The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the Pharmaceuticals, Biotechnology and Generics sectors of the overall health care industry, backed by a team of respected writers with many years of experience in the field.
Brazil’s final list of tariff increases in retaliation against USA less onerous than expected
12 March 2010
Brazil’s long-running battle with the USA over cotton subsidies, after the former won its argument
Latest Pharma Letter Articles
Pfizer ditches figitumumab in study with erlotinib and gets poor results from Sutent
12 March 2010
It was a bad news day for global behemoth Pfizer yesterday, as the company announced that it
Johnson & Johnson unit calls for re-examination of ceftobiprole, licensed from Basilea, submitted to CHMP
12 March 2010
Janssen-Cilag International NV, a subsidiary of US health care giant Johnson & Johnson, has
Increase in UK R&D spend led by pharma and biotech
12 March 2010
The top one thousand UK companies invested more than £26 billion ($39.26 billion) on developing
BioSante reveals positive leukemia vaccine results, sending the stock soaring
12 March 2010
USA-based BioSante Pharmaceuticals saw its shares leap 17% to $2.00 in early trading yesterday,
AstraZeneca pushes further into emerging market with Torrent deal
11 March 2010
Confirming its ongoing interest in emerging markets, Anglo-Swedish drug major AstraZeneca has
US generic drugmakers urge more funding of FDA, especially OGD division
11 March 2010
The Generic Pharmaceutical Association (GPhA) has reiterated its appeal for additional funding
Latest Events
BioTrinity 2010
LogiPharma 2010
News From the Web
Achillion Reports 2009 Fourth Quarter and Year-End Financial Results
12 March 2010 | CNNMoney.com (press release)
Ratiopharm Beats 2009 Goal, Says Auction Feedback 'Positive'
12 March 2010 | BusinessWeek
Caraco Pharmaceutical Laboratories Ltd declares launch of generic Eloxatin
12 March 2010 | Trading Markets (press release)
Most Filipinos fail to complete medication?DoH
12 March 2010 | Inquirer.net
Ranbaxy Labs eyes $3 bn turnover by 2012
12 March 2010 | Indian Express
AusBiotech 2010 National Conference
12 March 2010 | Lifescience Lab
Ranbaxy rebounds on robust outlook
12 March 2010 | BloombergUTV
Aveo Pharmaceuticals 9M-Share IPO Priced At $9 Each
11 March 2010 | Wall Street Journal
Xoma 4Q profit falls as contract revenue tumbles
11 March 2010 | The Associated Press
NPS Pharmaceuticals Reports 2009 Results and 2010 Outlook
11 March 2010 | MarketWatch (press release)
Investing in the Biotechnology Industry
11 March 2010 | Wealth Daily
- Transgene signs billion dollar deal with Novartis for TG4010 cancer vaccine option, but still disappoints investors
- US FDA issues complete response on Amgen’s Prolia with July action date
- FDA and European Medicines Agency agree to accept a single orphan drug designation annual report
- Abbott Labs bids $722 for Facet to enhances its biotech R&D pipeline, including daclizumab
- Japanese Pharma market seeing more foreign entrants
